Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$7.34 USD
-0.01 (-0.14%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $7.60 +0.26 (3.54%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Earnings News For RXRX
-
Recursion Pharmaceuticals: Q4 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for
-
Recursion Pharmaceuticals: Q3 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q2 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
-
Recursion Pharmaceuticals: Q1 Earnings Snapshot
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates
-
Recursion Pharmaceuticals: Q4 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q3 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q2 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates